Teva Pharma (TEVA) Tops Q1 EPS by 28c, Raises FY Guidance

Teva Pharma (NYSE: TEVA) reported Q1 EPS of $0.94, $0.28 better than the analyst estimate of $0.66. Revenue for the quarter came in at $5.1 billion versus the consensus estimate of $4.8 billion.

GUIDANCE:

Teva Pharma sees FY2018 EPS of $2.40-$2.65, versus the consensus of $2.48. Teva Pharma sees FY2018 revenue of $18.5-19 billion, versus the consensus of $18.7 billion.

For earnings history and earnings-related data on Teva Pharma (TEVA) click here.

You May Also Be Interested In

• AeroVironment restates quarterly financials, citing $89M goodwill error
• Ennis (EBF) Reports In-Line Q1 EPS
• Teva submits NDA for ecopipam to treat pediatric Tourette syndrome